ENDOCRINOLOGY IN PREGNANCY: BONE METABOLIC CHANGES DURING PREGNANCY: A PERIOD OF VULNERABILITY TO OSTEOPOROSIS AND FRACTURE.

Osteoporosis and fragility fracture have been diagnosed, although rarely. The condition, however, is transitory because there is no long-term data supporting the deleterious effect of pregnancy on bone mass or fracture risk. Prevention is limited by the lack of identifiable risk factors. When fractures are diagnosed, rest, analgesics, or when indicated, orthopedic intervention, have demonstrated efficacy. Systemic treatment with anti-osteoporotic drugs is effective, but the potential harm to the fetus imposes caution in their use.

Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter